Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors

Pečeliūnas, Valdas; Janiulioniene, Ausra; Matuzeviciene, Reda; Griškevičius, Laimonas

doi:10.1002/cyto.b.20601

Cited by 32 publications

(47 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we tested all the markers recommended by the European Myeloma Network1 except for CD27, since the loss of CD27 expression almost always is coupled with CD19-negativity in PCM 21. Among these, CD28 and CD117 were valuable additional markers which were not tested by Peceliunas and colleagues 17. In addition, 8-colour rather than 6-colour flow cytometry used in our study allowed us to better assess these markers in the same plasma cell population.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Peceliunas and colleagues studied 11 BM specimens obtained from patients with Hodgkin's lymphoma and observed similar immunophenotypic variations in plasma cells 17. They concluded that CD19, CD56, CD38, CD45 and CD20 expression characteristics were of little value in discriminating PCM cells from immunophenotypically atypical non-clonal plasma cells, challenging the approach of using surface marker immunophenotyping without assessing κ/λ clonality in detection of PCM MRD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

Liu

Lin

et al. 2012

J Clin Pathol

View full text Add to dashboard Cite

Plasma cell myeloma (PCM) exhibits immunophenotypic aberrancies that can be used for minimal residual disease (MRD) detection after therapy. The authors sought to determine whether non-neoplastic plasma cells, especially in the bone marrow (BM) post various therapies, would exhibit immunophenotypic variations interfering PCM MRD detection. The authors studied the flow cytometric immunophenotypes of non-neoplastic plasma cells from 50 BM specimens, including 12 untreated BM and 38 BM specimens from patients with non-plasmacytic haematological malignancies undergoing various therapies, and compared with 59 BM specimens positive for PCM MRD. Non-neoplastic plasma cells showed heterogeneous expressions of CD45 (78% (41-100)) and CD19 (80% (52-97)), and were negative for CD20 and CD117. CD56 was observed in a small subset (6% (0-37)) and CD28 in a larger subset (15% (0-59)) of non-neoplastic plasma cells, with the latter more frequently expressed in post-treatment BMs (p=0.01). However, despite a partial immunophenotypic overlap, PCM cells could be reliably discriminated from non-neoplastic plasma cells by the presence of a higher number of aberrancies (3 (1-6) vs 0 (0-2)) and stronger intensity and uniformity of aberrant expression (p<0.001 in each marker using a cut-off value). In addition, simultaneous assessment of cytoplasmic κ/λ with surface markers detected light chain restriction in all 59 PCM cases. In conclusion, non-neoplastic plasma cells in BM are more immunophenotypically heterogeneous than previously understood; however, these immunophenotypic variations differ from those of PCM. With advances in multicolour flow cytometry and application of recently validated markers, PCM MRD may still be reliably distinguished from non-neoplastic plasma cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

Liu

Lin

et al. 2012

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…It is worth to be mentioned that CD19 − CD56 − and CD19 + CD56 + PCs were also described in healthy donors' samples [35]. This CD19 − CD56 + aberrant immunophenotype was confirmed by Tembhare et al study: they analyzed 59 specimens of untreated patients with PCD (14 MGUS, 35 SMM, 10 MM) and 5 normal bone marrow specimens with no evidence of PCD.…”

Section: Immunophenotype Of Plasma Cellsmentioning

confidence: 55%

Flow cytometry in immunoglobulin light chain amyloidosis: Short review

et al. 2015

View full text Add to dashboard Cite

“…These data suggest that immunophenotype alone can provide a reliable sensitive detection of residual myeloma PC. Although in general this may be true, caution is advised since the immunophenotype of myeloma PC can change over time (13) and normal PC are heterogeneous in the expression of CD19 and CD56 (14). This raises the question whether immunophenotype alone, in the absence of a clonality assessment by the detection of cytoplasmic kappa and lambda light chains, can provide a reliable sensitive detection of MRD.…”

Section: Resultsmentioning

confidence: 99%

Inability of a monoclonal anti‐light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry

Velzen¹,

Blink²,

Bloem³

2012

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors

Cited by 32 publications

References 18 publications

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

Flow cytometry in immunoglobulin light chain amyloidosis: Short review

Inability of a monoclonal anti‐light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry

Contact Info

Product

Resources

About